Applied therapeutics announces positive sorbitol reduction data from the ongoing phase 3 inspire trial in sorbitol dehydrogenase (sord) deficiency

New york, feb. 16, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced positive sorbitol reduction data from the ongoing global phase 3 inspire trial. the inspire trial is a phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily oral at-007 in approximately 50 patients age 16-55 with sord deficiency in the us and europe. sord deficiency (also called sord neuropathy or cmt-sord) is a debilitating hereditary axonal neuropathy caused by mutations in the sorbitol dehydrogenase gene, leading to an inability to metabolize the sugar sorbitol, and resulting in accumulation of high levels of toxic sorbitol, which causes motor neuron degeneration and loss of mobility and motility. at-007 (govorestat) is a central nervous system penetrant aldose reductase inhibitor, which blocks conversion of glucose to sorbitol, and has previously been shown to reduce sorbitol levels in an open-label pilot study in patients with sord deficiency.
APLT Ratings Summary
APLT Quant Ranking